Back to top

Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged

Analyst Yun Zhong from Wedbush maintained a Buy rating on Sagimet Biosciences, Inc. Class A and keeping the price target at $28.00. Yun Zhong has g...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sagimet Biosciences Inc. (SGMT)